iSpecimen (ISPC) EBIT (2020 - 2026)

iSpecimen (ISPC) has reported EBIT for 7 consecutive years, with -$2.5 million the latest figure, recorded in Q1 2026.

• In Q1 2026, EBIT fell 54.93% year-over-year to -$2.5 million; the TTM figure through Mar 2026 stood at -$9.9 million (up 13.09% YoY), while the FY2025 annual figure was -$9.0 million, up 29.46% from the prior year.
• EBIT came in at -$2.5 million for Q1 2026 at iSpecimen, up from -$2.7 million in the prior quarter.
• The five-year high for EBIT was -$1.6 million in Q1 2025, with the low at -$5.8 million in Q4 2024.
• Average EBIT over 5 years is -$2.7 million, with a median of -$2.5 million recorded in 2023.
• Across the five-year window, EBIT plunged 150.19% in 2022 and surged 53.98% in 2025, its largest moves.
• Year by year, EBIT stood at -$2.1 million in 2022, then tumbled by 34.06% to -$2.9 million in 2023, then slumped by 103.43% to -$5.8 million in 2024, then soared by 53.98% to -$2.7 million in 2025, then advanced by 5.56% to -$2.5 million in 2026.
• According to Business Quant data, EBIT over the past three periods registered -$2.5 million, -$2.7 million, and -$2.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.